Fennec Pharmaceuticals (NASDAQ:FENC – Get Free Report) and aTyr Pharma (NASDAQ:LIFE – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.
Institutional and Insider Ownership
55.5% of Fennec Pharmaceuticals shares are held by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are held by institutional investors. 11.3% of Fennec Pharmaceuticals shares are held by insiders. Comparatively, 3.7% of aTyr Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Fennec Pharmaceuticals and aTyr Pharma’s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Fennec Pharmaceuticals | $21.25 million | 11.57 | -$16.05 million | ($0.61) | -14.87 |
| aTyr Pharma | $350,000.00 | 310.58 | -$50.39 million | ($0.96) | -1.67 |
Profitability
This table compares Fennec Pharmaceuticals and aTyr Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fennec Pharmaceuticals | -75.50% | N/A | -73.64% |
| aTyr Pharma | N/A | -49.84% | -39.12% |
Analyst Ratings
This is a summary of recent ratings and recommmendations for Fennec Pharmaceuticals and aTyr Pharma, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fennec Pharmaceuticals | 0 | 0 | 3 | 0 | 3.00 |
| aTyr Pharma | 0 | 1 | 3 | 0 | 2.75 |
Fennec Pharmaceuticals presently has a consensus price target of $17.33, indicating a potential upside of 91.11%. aTyr Pharma has a consensus price target of $23.67, indicating a potential upside of 1,379.17%. Given aTyr Pharma’s higher probable upside, analysts clearly believe aTyr Pharma is more favorable than Fennec Pharmaceuticals.
Volatility & Risk
Fennec Pharmaceuticals has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500.
Summary
aTyr Pharma beats Fennec Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
About aTyr Pharma
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
